Jean-Charles Wirth and Danny Bar-Zohar are set to assume the life science and healthcare CEO roles respectively.

Peter Guenter will retire as CEO of Merck KGaA’s healthcare business on June 1, one of several personnel moves that the German pharma announced earlier ...

Germany's Merck KGaA said on Tuesday its lab equipment division and its pharmaceuticals division would be under new ...

Merck Foundation Chief Executive Officer (CEO) advanced Cancer Care in Africa by providing 194 Oncology Scholarships in ...

Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg.

In an interview in January, Merck's CEO said a recovery in sales growth at its major businesses would allow the company to take a cautious approach to buying other companies, which are expensively ...

A pharma giant expresses interest in a Stamford biotech company after striking a deal worth up to $1.3 billion for a New ...

Investors are undervaluing promising drug candidates on the horizon for the two pharma giants, write Yale SOM’s Jeffrey Sonnenfeld and co-author Steven Tian.

After a slow 2024, dealmaking in the U.S. healthcare sector is picking up. Springworks has a market value of $3 billion.

Inhibikase Therapeutics (IKT) appointed Mark Iwicki as the company’s CEO, replacing Milton Werner, founder of Inhibikase, effective February ...

Big Tech and pharmaceutical companies are accelerating the implementation of artificial intelligence in the healthcare ...